Ardelyx, Inc. (ARDX) financial statements and ratios from SEC XBRL: revenue $0.5B (TTM), net margin -15.1%, revenue growth 23.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $407.32M |
| Revenue (TTM) | $0.5B |
| Net Margin | -15.1% |
| Operating Margin (TTM) | -7.9% |
| Net Debt / EBITDA | -5.0 |
| Revenue Growth (YoY) | 23.8% |
| EPS Growth (YoY) | -12.5% |
| FCF Growth (YoY) | -75.3% |
| Price / Book | 6.50 |
| Price / Sales | 2.15 |
| FCF Yield | -1.9% |
| Altman Z-Score | 0.31 (distress) |
| Piotroski F-Score | 3/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
ARDX overview · ARDX earnings · ARDX KPIs · ARDX documents · ARDX ownership · ARDX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.